Colorectal Cancer Competitive Landscape: 195+ Companies Advancing 200+ Clinical-Stage Therapies Across Global Trials, Reports DelveInsight

Leading companies active in the colorectal cancer space include Nektar Therapeutics, ALX Oncology Inc., Processa Pharmaceuticals, Guojian Pharmaceutical, Gritstone Bio, Daiichi Sankyo, Novartis Pharmaceuticals, Shanghai Henlius Biotech, Sumitomo Pharma Oncology, Purple Biotech Ltd., Amgen, Mirati Therapeutics, Plus Therapeutics, Sparrow Pharmaceuticals, Sirnaomics, G1 Therapeutics, Apollomics, and several others.
According to DelveInsight's latest evaluation, the "Colorectal Cancer Pipeline Insight" report delivers a comprehensive analysis of both the clinical and commercial environment. The study highlights more than 195 companies actively advancing 200+ therapies across multiple stages of development. It provides detailed insights into clinical trials, treatment modalities, mechanisms of action (MoA), routes of administration (RoA), and company-level advancements, underscoring the fast-paced transformation of the CRC treatment landscape.

Efforts to combat colorectal cancer (CRC) one of the most prevalent and fatal malignancies globally are gaining strong momentum, driven by breakthroughs in clinical research, therapeutic innovation, and regulatory progress.

Request for Sample PDF Report for Colorectal Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Recent Regulatory and Clinical Milestones in Colorectal Cancer (2024-2025)

* October 2025: Merus N.V. announced interim Phase II data (cutoff July 29, 2025) for its bispecific antibody petosemtamab, evaluated in combination with FOLFOX/FOLFIRI in first- and second-line metastatic CRC and as monotherapy in later-line disease.
* October 2025: Nouscom reported encouraging Phase II outcomes for NOUS-209 combined with pembrolizumab in MSI-H metastatic CRC patients resistant to prior anti-PD-1 therapy.
* September 2025: Artios Pharma received FDA Fast Track designation for alnodesertib, an ATR inhibitor combined with low-dose irinotecan, for ATM-negative third-line metastatic CRC.
* March 27, 2025: LIXTE Biotechnology Holdings, alongside the Netherlands Cancer Institute and Roche, initiated dosing in a clinical trial for MSI-Low metastatic CRC.
* January 25, 2025: Exelixis presented Phase Ib/II STELLAR-001 trial data on zanzalintinib plus atezolizumab at ASCO GI 2025.
* January 2025: Marengo Therapeutics secured FDA Fast Track designation for invikafusp alfa (STAR0602) in advanced TMB-high CRC.
* January 2025: Mirror Biologics partnered with Merck KGaA to evaluate AlloStim with Bavencio in Phase II metastatic CRC trials.
* January 16, 2025: FDA approved Lumakras (sotorasib) with Vectibix (panitumumab) for KRAS G12C-mutated metastatic CRC.
* December 2024: Pfizer obtained FDA approval for BRAFTOVI plus cetuximab and mFOLFOX6 under the Project FrontRunner initiative for BRAF V600E-positive CRC.
* September 2024: FRUZAQLA (fruquintinib) was approved as an oral targeted therapy for metastatic CRC.
* January 2024: Bristol Myers Squibb reported positive Phase III CheckMate-8HW results for Opdivo plus Yervoy in MSI-H/dMMR metastatic CRC.
* November 2023: FDA approved fruquintinib for previously treated metastatic CRC patients.

Get a Free Sample PDF Report to know more about Colorectal Cancer Pipeline Therapeutic Assessment- Colorectal Cancer Pipeline Drugs [https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Insights From the Colorectal Cancer Pipeline Report

* Global R&D Activity: Over 195 organizations are developing more than 200 CRC therapies spanning preclinical research through Phase I, II, and III studies, with multiple candidates approaching commercialization.
* Major Industry Players: Companies such as Plus Therapeutics, Processa Pharmaceuticals, Shanghai Henlius Biotech, Apollomics, Novartis, Sumitomo Pharma Oncology, Purple Biotech, Nektar Therapeutics, ALX Oncology, Daiichi Sankyo, Gritstone Bio, G1 Therapeutics, Amgen, Mirati Therapeutics, and others are driving innovation in CRC treatment.
* Notable Pipeline Candidates: Therapies such as 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras, and MRTX849 are expected to shape future treatment paradigms.
* Diverse Mechanisms: The pipeline features monoclonal antibodies, small molecules, peptides, gene therapies, and immune checkpoint inhibitors.
* Administration Options: Therapeutics are being developed across oral, intravenous, subcutaneous, parenteral, and topical routes to enhance patient compliance.
* Strategic Collaborations: Increased partnerships between industry and academia are expediting development timelines and regulatory pathways.

Stay ahead of the curve with DelveInsight's "Colorectal Cancer Pipeline Insight, 2025" report. Gain exclusive access to detailed analyses of 195+ companies, 200+ emerging therapies, regulatory milestones (EMA, PDMA, FDA), and the latest clinical trial insights shaping the colorectal cancer treatment landscape @ [https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Colorectal Cancer Overview

Colorectal cancer remains a major global health burden. In 2025, approximately 1.9 million new casesand over 900,000 Cdeaths are projected worldwide. CRC ranks as the third most commonly diagnosed cancer and the second leading cause of cancer mortality. In the U.S. alone, an estimated 154,000 new cases and 53,000 deaths are anticipated. Alarmingly, incidence rates are rising among individuals under 55, emphasizing the importance of early screening, diagnosis, and therapeutic innovation.

Promising Emerging Colorectal Cancer Therapies

Key pipeline candidates include 188RNL-BAM, PCS11T, HLX13, Adagrasib, Zanzalintinib, EO2040, Etrumadenant, LYL845, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, and Lumakras. These therapies target KRAS, BRAF, immune checkpoints, angiogenesis, and T-cell signaling pathways.

Further Colorectal Cancer product details are provided in the report. Download the Colorectal Cancer pipeline report to learn more about the [https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Colorectal Cancer Therapeutic Assessment

* Molecule Classes: Monoclonal antibodies, small molecules, peptides, polymers, and gene therapies
* Routes of Administration: Oral, intravenous, subcutaneous, parenteral, topical
* Development Stages: Phase III, Phase II, Phase I, preclinical, discovery, and discontinued programs

Colorectal Cancer Market Dynamics

Colorectal Cancer Market Drivers:

Rising disease incidence, improved screening, advances in immuno-oncology and targeted therapies, and expanding healthcare access are fueling market growth.

Colorectal Cancer Market Barriers:

High treatment costs, regulatory complexity, delayed diagnosis, biological heterogeneity, therapy resistance, and safety concerns continue to challenge widespread adoption.

Download Sample PDF Report to know more about [https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Colorectal Cancer Market Report

* Geographic Coverage: Global
* Companies Covered: Amgen, Pfizer, Novartis, Daiichi Sankyo, Mirati, G1 Therapeutics, Plus Therapeutics, Processa, Henlius, Apollomics, and others
* Therapy Types: From antibodies to gene-based treatments
* Segmentation: By stage, MoA, RoA, and molecule type
* Additional Insights: Collaborations, licensing deals, M&A activity, and funding trends

About DelveInsight

DelveInsight is a premier life sciences market research and consulting firm, offering end-to-end support across drug development, market intelligence, and healthcare strategy. The company empowers pharma and biotech organizations to navigate complexity, unlock growth opportunities, and accelerate innovation across oncology and other therapeutic areas.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=colorectal-cancer-competitive-landscape-195-companies-advancing-200-clinicalstage-therapies-across-global-trials-reports-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.